这么大的公司，股价也_老虎社区_美港股上老虎 - 老虎社区

沧海一粟涛涛

这么大的公司，股价也跟神经病似的

诺和诺德Q1业绩好坏参半，下调全年销售额和盈利预期

诺和诺德Q1销售额不及市场预期

诺和诺德一季度销售额780.9亿丹麦克朗，低于市场预期

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

1

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":432509599621528,"tweetId":"432509599621528","gmtCreate":1746603534700,"gmtModify":1746605543007,"author":{"id":3523587098717559,"idStr":"3523587098717559","authorId":3523587098717559,"authorIdStr":"3523587098717559","name":"沧海一粟涛涛","avatar":"https://static.tigerbbs.com/2fa748518a2483ea79bacfdb91ea26ef","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":42,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":32,"starInvestorOrderShareNum":146,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":-76.76,"showRor":true,"winRationPercentage":58.917197,"tradeVolumeEst":0},"themes":[{"themeId":"a849caf5bc904a5aa5e1ab4df4fed626","categoryId":"2929bb7468f5415f853fd96fb35d7c3b","name":"诺和诺德Q1销售额不及市场预期","type":2,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":a849caf5bc904a5aa5e1ab4df4fed626}&rnconfig={\"headerBarHidden\": true}","description":"诺和诺德一季度销售额780.9亿丹麦克朗，低于市场预期"}],"images":[],"coverImages":[],"html":"<html><head></head><body><p>这么大的公司，股价也跟神经病似的</p></body></html>","htmlText":"<html><head></head><body><p>这么大的公司，股价也跟神经病似的</p></body></html>","text":"这么大的公司，股价也跟神经病似的","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/432509599621528","repostId":1163918150,"repostType":2,"repost":{"id":"1163918150","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1746596256,"share":"https://www.laohu8.com/m/news/1163918150?lang=&edition=full","pubTime":"2025-05-07 13:37","market":"us","language":"zh","title":"诺和诺德Q1业绩好坏参半，下调全年销售额和盈利预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1163918150","media":"老虎资讯综合","summary":"$诺和诺德(NVO)$夜盘短线下跌近3%！一季度销售额780.9亿丹麦克朗，预估787亿丹麦克朗。","content":"<html><head></head><body><p>5月7日，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>发布2025年第一季度业绩。财报显示，第一季度销售额780.9亿丹麦克朗，预估787亿丹麦克朗；第一季度EBIT387.9亿丹麦克朗，预估371.2亿丹麦克朗；第一季度净利润290.3亿丹麦克朗，预估279.1亿丹麦克朗；第一季度税前利润370.3亿丹麦克朗，预估352.6亿丹麦克朗。</p><p>第一季度减肥药Wegovy销售额173.6亿丹麦克朗，预估189.8亿丹麦克朗；第一季度Ozempic销售额327.2亿丹麦克朗，预估323.2亿丹麦克朗。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/340b7980f8249c48b713b858c466fc9a\" title=\"\" tg-width=\"523\" tg-height=\"750\"/></p><p>就2025年的展望而言，目前预计销售额增长率（按固定汇率计算）为13-21%，市场预估增长18.6%，此前预估增长16%-24%；营业利润增长率（按固定汇率计算）为16-24%，市场预估增长22.4%，此前预计增长19%-27%。</p><p>以丹麦克朗计算的销售额和营业利润增长率预计分别比固定汇率低3个百分点和5个百分点。更新后的销售预期反映了美国品牌GLP-1药物的渗透率低于预期，这主要受到复合GLP-1的影响。</p><p>财报发布后，诺和诺德美股夜盘一度跌超4%，现涨近5%；诺和诺德CEO：2025年将在“更多国家”推出减肥药Wegovy。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f63610c220a2813913093f7df4074986\" tg-width=\"868\" tg-height=\"829\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德Q1业绩好坏参半，下调全年销售额和盈利预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德Q1业绩好坏参半，下调全年销售额和盈利预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-05-07 13:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>5月7日，<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>发布2025年第一季度业绩。财报显示，第一季度销售额780.9亿丹麦克朗，预估787亿丹麦克朗；第一季度EBIT387.9亿丹麦克朗，预估371.2亿丹麦克朗；第一季度净利润290.3亿丹麦克朗，预估279.1亿丹麦克朗；第一季度税前利润370.3亿丹麦克朗，预估352.6亿丹麦克朗。</p><p>第一季度减肥药Wegovy销售额173.6亿丹麦克朗，预估189.8亿丹麦克朗；第一季度Ozempic销售额327.2亿丹麦克朗，预估323.2亿丹麦克朗。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/340b7980f8249c48b713b858c466fc9a\" title=\"\" tg-width=\"523\" tg-height=\"750\"/></p><p>就2025年的展望而言，目前预计销售额增长率（按固定汇率计算）为13-21%，市场预估增长18.6%，此前预估增长16%-24%；营业利润增长率（按固定汇率计算）为16-24%，市场预估增长22.4%，此前预计增长19%-27%。</p><p>以丹麦克朗计算的销售额和营业利润增长率预计分别比固定汇率低3个百分点和5个百分点。更新后的销售预期反映了美国品牌GLP-1药物的渗透率低于预期，这主要受到复合GLP-1的影响。</p><p>财报发布后，诺和诺德美股夜盘一度跌超4%，现涨近5%；诺和诺德CEO：2025年将在“更多国家”推出减肥药Wegovy。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f63610c220a2813913093f7df4074986\" tg-width=\"868\" tg-height=\"829\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","BK4532":"文艺复兴科技持仓","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","BK4585":"ETF&股票定投概念","NVO":"诺和诺德"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163918150","content_text":"5月7日，诺和诺德发布2025年第一季度业绩。财报显示，第一季度销售额780.9亿丹麦克朗，预估787亿丹麦克朗；第一季度EBIT387.9亿丹麦克朗，预估371.2亿丹麦克朗；第一季度净利润290.3亿丹麦克朗，预估279.1亿丹麦克朗；第一季度税前利润370.3亿丹麦克朗，预估352.6亿丹麦克朗。第一季度减肥药Wegovy销售额173.6亿丹麦克朗，预估189.8亿丹麦克朗；第一季度Ozempic销售额327.2亿丹麦克朗，预估323.2亿丹麦克朗。就2025年的展望而言，目前预计销售额增长率（按固定汇率计算）为13-21%，市场预估增长18.6%，此前预估增长16%-24%；营业利润增长率（按固定汇率计算）为16-24%，市场预估增长22.4%，此前预计增长19%-27%。以丹麦克朗计算的销售额和营业利润增长率预计分别比固定汇率低3个百分点和5个百分点。更新后的销售预期反映了美国品牌GLP-1药物的渗透率低于预期，这主要受到复合GLP-1的影响。财报发布后，诺和诺德美股夜盘一度跌超4%，现涨近5%；诺和诺德CEO：2025年将在“更多国家”推出减肥药Wegovy。","news_type":1,"symbols_score_info":{"NVO":1}},"isVote":1,"tweetType":1,"viewCount":799,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":31,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/432509599621528"}